Last $2.25 USD
Change Today 0.00 / 0.00%
Volume 328.0K
CYTX On Other Exchanges
As of 12:29 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/5/13 - $3.93
52 Week Low
11/1/13 - $2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

No Related Businessweek News Found

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. In addition, Cytori Therapeutics, Inc. develops products in therapeutic areas, such as the treatment of thermal burns, and orthopedics and sports medicine indications, as well as specifically heart failure due to ischemic heart disease. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, clinics, tissue banks, stem cell banking companies, and researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

115 Employees
Last Reported Date: 03/14/14
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $406.6K
Co-Founder, Vice Chairman, Managing Director ...
Total Annual Compensation: $467.9K
Chief Financial Officer
Total Annual Compensation: $389.9K
President of Asia Pacific
Total Annual Compensation: $454.4K
Executive Vice President of Marketing & Sales
Total Annual Compensation: $329.5K
Compensation as of Fiscal Year 2012.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics, Inc. Announces the Publication of Safety and Efficacy Data

Cytori Therapeutics, Inc. announced the publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. Final data from the Company's PRECISE trial, a 27-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA), demonstrated statistically significant differences in cardiac functional capacity between treated and placebo groups and will appear in an upcoming issue of the American Heart Journal. Cytori Cell Therapy is a mixed population of adipose derived regenerative cells (ADRCs(TM)) extracted from a patient's own adipose tissue using Cytori's proprietary Celution(R) System. In the PRECISE trial, all patients were treated with standard-of-care and subsequently underwent a liposuction procedure. Each patient's adipose tissue was processed using Cytori's proprietary Celution(R) System to prepare the cell therapy. Cells (n=21) or placebo (n=6) were injected into areas of the heart muscle that were severely damaged but still viable and reversible using the NOGA XP System. Cytori is currently enrolling patients in the U.S. ATHENA and ATHENA II trials, both 45 patient prospective, randomized, double-blind, placebo-controlled trials investigating a lower and a higher dose, respectively, of Cytori Cell Therapy in a similar patient population as PRECISE. In addition, Cytori has received a CE Mark for the Intravase(R) reagent to be used with the Celution(R) System for intravascular delivery. The Intravase(R) CE Mark allows for targeted sales to physicians conducting independent research for intravascular indications. Cytori has a global patent estate related to the treatment of heart disease that includes 48 patents with 521 claims across 28 countries, including multiple countries in Europe, major Asian markets such as Japan and China, as well as other emerging markets.

Cytori Therapeutics, Inc. Announces Management Changes

Cytori Therapeutics announced that Christopher Calhoun, Chief Executive Officer and Director is retiring from the position of CEO of the company, effective immediately. The board of directors has named Dr. Marc Hedrick to the position of CEO, in addition to his current responsibilities as President and Director. During a transition period, Mr. Calhoun will remain a director on Cytori's board and will assume the position of Managing Director. As Managing Director, he will focus principally on Cytori's international business development efforts until his retirement from the company on July 1, 2014.

Cytori Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Financial Guidance for the Year 2014

Cytori Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported product revenues of USD 2,706,000 compared to USD 3,967,000 a year ago. Operating loss was USD 9,118,000 compared to USD 2,761,000 a year ago. Net loss was USD 10,041,000 compared to USD 3,823,000 a year ago. Basic and diluted loss per share was USD 0.14 compared to USD 0.06 a year ago. Net loss narrowed principally due to gains associated with strategic transactions. For the twelve months, the company reported product revenues of USD 7,122,000 compared to USD 8,709,000 a year ago. Operating loss was USD 30,679,000 compared to USD 28,418,000 a year ago. Net loss was USD 26,177,000 compared to USD 32,279,000 a year ago. Basic and diluted loss per share was USD 0.39 compared to USD 0.55 a year ago. Net cash used in operating activities were USD 34,563,000 compared to USD 32,193,000 a year ago. Purchases of property and equipment were USD 519,000 compared to USD 1,204,000 a year ago. In 2014, the company expects to continue to realize modest product revenue growth, consistent with the current predominantly research oriented customer base. Contract revenues may increase or decrease significantly depending on the outcome of an upcoming review process with BARDA. Change in research and development expenses will depend primarily on the outcome of the BARDA decision. SG&A expenses are projected to remain flat in 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $2.25 USD 0.00

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.06 USD +0.0044
Athersys Inc $2.70 USD +0.06
BioTime Inc $2.77 USD +0.05
NeoStem Inc $6.54 USD +0.11
Pluristem Therapeutics Inc $3.49 USD +0.085
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 51.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at